BRAF-mutated CRC has a poor prognosis and limited treatment options. Read my thoughts on how combinations with BRAF inhibitors are offering promising benefits for this challenging population.
As patients progress through first-line and second-line therapy, selection of therapy becomes more complicated and nuanced. Here’s how I navigate the multiple treatment options.
In this commentary on the treatment of metastatic colorectal cancer, I explore areas of consensus and controversy among experts including management of MSI-high/MMR-deficient tumors, treatment of transverse primaries, management of tumors with BRAF V600E mutations, and approaches in later lines of therapy.
In this case study from my clinic on the treatment of a new mother with metastatic colon cancer, I explore her questions, options, therapy selection, and follow-up.
This interactive treatment decision aid will let you compare your choice of therapy for patients with metastatic CRC with expert recommendations from Tanios Bekaii-Saab, MD, FACP; George A. Fisher, MD, PhD; Scott Kopetz, MD, PhD, FACP; John Strickler, MD; and Alan P. Venook, MD.
In this CME/CE-certified activity, Tanios Bekaii-Saab, MD, FACP, reviews key data supporting evolving treatment choices for patients with metastatic colorectal cancer.
In this downloadable slideset, Tanios Bekaii-Saab, MD, FACP, reviews current management strategies for patients with metastatic CRC along with key data supporting each approach.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.